Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth

IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical journal 2022-09, Vol.479 (17), p.1807-1824
Hauptverfasser: Korac, Ksenija, Rajasekaran, Devaraja, Sniegowski, Tyler, Schniers, Bradley K, Ibrahim, Andrew F, Bhutia, Yangzom D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1824
container_issue 17
container_start_page 1807
container_title Biochemical journal
container_volume 479
creator Korac, Ksenija
Rajasekaran, Devaraja
Sniegowski, Tyler
Schniers, Bradley K
Ibrahim, Andrew F
Bhutia, Yangzom D
description IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1.
doi_str_mv 10.1042/BCJ20210851
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9472820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2705752690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2961-9c3fb52fd3beffa03c4083de6781932a14a7cbbfb5f3860c357f20c2c80abab33</originalsourceid><addsrcrecordid>eNpVkUtP3TAQha0KVG5pV90jL5FK6NjOc1OJXspLSGzatTVxxlyj3Di1E1p2_HR8eQlWHvt8PuPxYeyrgEMBufz-c3khQQqoC_GBLUReQVZXst5iC5BlnpVJ22GfYrwBEDnk8JHtqKJpKmhgwe6XGFrX-REPOA4czeRucfKBe8sx3PV8ddcFbxLkBx7I0JjEAx7ncQwUI0V-fnwlOP1_3LoEuYGPOJhAODnDTSopJOuOd7Q53FyZ5nXqcB38v2n1mW1b7CN9eV532Z-TX7-XZ9nl1en58ugyM7IpRdYYZdtC2k61ZC2CMjnUqqOyqkWjJIocK9O2ibGqLsGoorISjDQ1YIutUrvsx5PvOLdr6gwNU8Bej8Gt05zao9PvlcGt9LW_1U2ePlNCMth_Ngj-70xx0msXDfU9DuTnqGUFRVXIstmg355QE3yMgexrGwF6k5l-k1mi996-7JV9CUk9AE3QlRk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2705752690</pqid></control><display><type>article</type><title>Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth</title><source>MEDLINE</source><source>PubMed Central(OpenAccess)</source><source>Free E-Journal (出版社公開部分のみ)</source><creator>Korac, Ksenija ; Rajasekaran, Devaraja ; Sniegowski, Tyler ; Schniers, Bradley K ; Ibrahim, Andrew F ; Bhutia, Yangzom D</creator><creatorcontrib>Korac, Ksenija ; Rajasekaran, Devaraja ; Sniegowski, Tyler ; Schniers, Bradley K ; Ibrahim, Andrew F ; Bhutia, Yangzom D</creatorcontrib><description>IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1.</description><identifier>ISSN: 0264-6021</identifier><identifier>EISSN: 1470-8728</identifier><identifier>DOI: 10.1042/BCJ20210851</identifier><identifier>PMID: 35997090</identifier><language>eng</language><publisher>England: Portland Press Ltd</publisher><subject>Animals ; Cancer ; Carbidopa - pharmacology ; Gene Expression &amp; Regulation ; Indoleamine-Pyrrole 2,3,-Dioxygenase ; Janus Kinases - metabolism ; Kynurenine - metabolism ; Mice ; Mice, Nude ; Pancreatic Neoplasms ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Receptors, Aryl Hydrocarbon - metabolism ; Signal Transduction ; Signaling ; STAT Transcription Factors - metabolism ; Tryptophan - metabolism</subject><ispartof>Biochemical journal, 2022-09, Vol.479 (17), p.1807-1824</ispartof><rights>2022 The Author(s).</rights><rights>2022 The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2961-9c3fb52fd3beffa03c4083de6781932a14a7cbbfb5f3860c357f20c2c80abab33</citedby><cites>FETCH-LOGICAL-c2961-9c3fb52fd3beffa03c4083de6781932a14a7cbbfb5f3860c357f20c2c80abab33</cites><orcidid>0000-0002-6927-075X ; 0000-0002-7120-2537</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472820/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472820/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35997090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korac, Ksenija</creatorcontrib><creatorcontrib>Rajasekaran, Devaraja</creatorcontrib><creatorcontrib>Sniegowski, Tyler</creatorcontrib><creatorcontrib>Schniers, Bradley K</creatorcontrib><creatorcontrib>Ibrahim, Andrew F</creatorcontrib><creatorcontrib>Bhutia, Yangzom D</creatorcontrib><title>Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth</title><title>Biochemical journal</title><addtitle>Biochem J</addtitle><description>IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1.</description><subject>Animals</subject><subject>Cancer</subject><subject>Carbidopa - pharmacology</subject><subject>Gene Expression &amp; Regulation</subject><subject>Indoleamine-Pyrrole 2,3,-Dioxygenase</subject><subject>Janus Kinases - metabolism</subject><subject>Kynurenine - metabolism</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Receptors, Aryl Hydrocarbon - metabolism</subject><subject>Signal Transduction</subject><subject>Signaling</subject><subject>STAT Transcription Factors - metabolism</subject><subject>Tryptophan - metabolism</subject><issn>0264-6021</issn><issn>1470-8728</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtP3TAQha0KVG5pV90jL5FK6NjOc1OJXspLSGzatTVxxlyj3Di1E1p2_HR8eQlWHvt8PuPxYeyrgEMBufz-c3khQQqoC_GBLUReQVZXst5iC5BlnpVJ22GfYrwBEDnk8JHtqKJpKmhgwe6XGFrX-REPOA4czeRucfKBe8sx3PV8ddcFbxLkBx7I0JjEAx7ncQwUI0V-fnwlOP1_3LoEuYGPOJhAODnDTSopJOuOd7Q53FyZ5nXqcB38v2n1mW1b7CN9eV532Z-TX7-XZ9nl1en58ugyM7IpRdYYZdtC2k61ZC2CMjnUqqOyqkWjJIocK9O2ibGqLsGoorISjDQ1YIutUrvsx5PvOLdr6gwNU8Bej8Gt05zao9PvlcGt9LW_1U2ePlNCMth_Ngj-70xx0msXDfU9DuTnqGUFRVXIstmg355QE3yMgexrGwF6k5l-k1mi996-7JV9CUk9AE3QlRk</recordid><startdate>20220916</startdate><enddate>20220916</enddate><creator>Korac, Ksenija</creator><creator>Rajasekaran, Devaraja</creator><creator>Sniegowski, Tyler</creator><creator>Schniers, Bradley K</creator><creator>Ibrahim, Andrew F</creator><creator>Bhutia, Yangzom D</creator><general>Portland Press Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6927-075X</orcidid><orcidid>https://orcid.org/0000-0002-7120-2537</orcidid></search><sort><creationdate>20220916</creationdate><title>Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth</title><author>Korac, Ksenija ; Rajasekaran, Devaraja ; Sniegowski, Tyler ; Schniers, Bradley K ; Ibrahim, Andrew F ; Bhutia, Yangzom D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2961-9c3fb52fd3beffa03c4083de6781932a14a7cbbfb5f3860c357f20c2c80abab33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Cancer</topic><topic>Carbidopa - pharmacology</topic><topic>Gene Expression &amp; Regulation</topic><topic>Indoleamine-Pyrrole 2,3,-Dioxygenase</topic><topic>Janus Kinases - metabolism</topic><topic>Kynurenine - metabolism</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Receptors, Aryl Hydrocarbon - metabolism</topic><topic>Signal Transduction</topic><topic>Signaling</topic><topic>STAT Transcription Factors - metabolism</topic><topic>Tryptophan - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korac, Ksenija</creatorcontrib><creatorcontrib>Rajasekaran, Devaraja</creatorcontrib><creatorcontrib>Sniegowski, Tyler</creatorcontrib><creatorcontrib>Schniers, Bradley K</creatorcontrib><creatorcontrib>Ibrahim, Andrew F</creatorcontrib><creatorcontrib>Bhutia, Yangzom D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korac, Ksenija</au><au>Rajasekaran, Devaraja</au><au>Sniegowski, Tyler</au><au>Schniers, Bradley K</au><au>Ibrahim, Andrew F</au><au>Bhutia, Yangzom D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth</atitle><jtitle>Biochemical journal</jtitle><addtitle>Biochem J</addtitle><date>2022-09-16</date><risdate>2022</risdate><volume>479</volume><issue>17</issue><spage>1807</spage><epage>1824</epage><pages>1807-1824</pages><issn>0264-6021</issn><eissn>1470-8728</eissn><abstract>IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1.</abstract><cop>England</cop><pub>Portland Press Ltd</pub><pmid>35997090</pmid><doi>10.1042/BCJ20210851</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-6927-075X</orcidid><orcidid>https://orcid.org/0000-0002-7120-2537</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-6021
ispartof Biochemical journal, 2022-09, Vol.479 (17), p.1807-1824
issn 0264-6021
1470-8728
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9472820
source MEDLINE; PubMed Central(OpenAccess); Free E-Journal (出版社公開部分のみ)
subjects Animals
Cancer
Carbidopa - pharmacology
Gene Expression & Regulation
Indoleamine-Pyrrole 2,3,-Dioxygenase
Janus Kinases - metabolism
Kynurenine - metabolism
Mice
Mice, Nude
Pancreatic Neoplasms
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Receptors, Aryl Hydrocarbon - metabolism
Signal Transduction
Signaling
STAT Transcription Factors - metabolism
Tryptophan - metabolism
title Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A54%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carbidopa,%20an%20activator%20of%20aryl%20hydrocarbon%20receptor,%20suppresses%20IDO1%20expression%20in%20pancreatic%20cancer%20and%20decreases%20tumor%20growth&rft.jtitle=Biochemical%20journal&rft.au=Korac,%20Ksenija&rft.date=2022-09-16&rft.volume=479&rft.issue=17&rft.spage=1807&rft.epage=1824&rft.pages=1807-1824&rft.issn=0264-6021&rft.eissn=1470-8728&rft_id=info:doi/10.1042/BCJ20210851&rft_dat=%3Cproquest_pubme%3E2705752690%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2705752690&rft_id=info:pmid/35997090&rfr_iscdi=true